Foghorn Therapeutics Inc. (NASDAQ: FHTX)
$6.60
+0.3500 ( +5.60% ) 182.2K
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Market Data
Open
$6.60
Previous close
$6.25
Volume
182.2K
Market cap
$369.04M
Day range
$6.17 - $6.98
52 week range
$2.70 - $9.97
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 56 | Nov 02, 2023 |
8-k | 8K-related | 49 | Nov 02, 2023 |
4 | Insider transactions | 1 | Sep 13, 2023 |
3 | Insider transactions | 2 | Sep 13, 2023 |
4 | Insider transactions | 1 | Sep 13, 2023 |
8-k | 8K-related | 77 | Sep 08, 2023 |
8-k | 8K-related | 13 | Aug 31, 2023 |
4 | Insider transactions | 1 | Aug 18, 2023 |
4 | Insider transactions | 1 | Aug 18, 2023 |
8-k | 8K-related | 12 | Aug 10, 2023 |